ライフサイエンスコーパス: immunodeficient

1 e engrafted into neonatal mice that are both immunodeficient and deficient for myelin basic protein.

2 ve transfer of diabetes by CD4(+) T cells to immunodeficient and diabetes-resistant NOD.scid mice was

3 lts in a significant increase in survival in immunodeficient and immunocompetent models of pHGG and D

4 n eradicated by CD19-specific CAR-T cells in immunodeficient and immunocompetent mouse models.

5 r stromal interaction molecule 1 (STIM1) are immunodeficient and prone to chronic infection by variou

6 ice, AtmR3016H (Atm(R/R) ) mice were viable, immunodeficient, and displayed spontaneous craniofacial

7 ACs were transplanted into adrenalectomized, immunodeficient, and immunocompetent rats.

8 -TAM pool, using orthotopically xenografted, immunodeficient, and syngeneic mouse models with genetic

9 tence of TIL after adoptive transfer into an immunodeficient animal model and augments antitumor immu

10 rounds as a model, we show that ticks fed on immunodeficient animals demonstrate decreased fibrinogen

11 dation product) were evident in ticks fed on immunodeficient animals in comparison to ticks fed on im

12 orgement weights were noted for ticks fed on immunodeficient animals in comparison to ticks fed on im

13 syringae strains into virulent pathogens in immunodeficient Arabidopsis thaliana under high humidity

14 activity in immunocompetent C57BL/6 but not immunodeficient athymic mice, leading to specific immune

15 Immunodeficient Balb/c IL2rgammaRag2 mice were transplan

16 in the abdominal aorta of a severe combined immunodeficient Beige mouse model supports normal blood

17 RAG2/IL2RG deficient pigs were immunodeficient, characterized by depletion of lymphocyt

18 Humanized nonobese diabetic severe combined immunodeficient common gamma chain-deficient stem cell f

19 ncer cells are orthotopically implanted into immunodeficient consomic strains and tumor metrics are q

20 in the percentage of dying (TUNEL+) cells in immunodeficient dystrophic mouse muscles at the times af

21 Nonobese diabetic severe combined immunodeficient gammac(-/-) (NSG) mice received intraper

22 These results suggest that GE immunodeficient gnotobiotic pigs serve as a novel model

23 was attenuated in C57BL/6 wild-type mice and immunodeficient gp91(-/-) phox mice and was effective as

24 n Toll-like receptor signaling, are severely immunodeficient, highlighting the paramount role of IRAK

25 can protect against enteric pathogens in an immunodeficient host.

26 ansformed by E1A/Ras and generated tumors in immunodeficient hosts as efficiently as wild-type (WT) t

27 a protocol to engineer humanized bone within immunodeficient hosts, which can be adapted to study the

28 ctions caused by viable vaccine organisms in immunodeficient hosts.

29 V infection and pathological consequences in immunodeficient hosts.

30 disease that occur during acute infection of immunodeficient hosts.

31 ha mutation; and hu cord blood-reconstituted immunodeficient, hu cytokine-secreting, mice that have l

32 nd persist longer after adoptive transfer in immunodeficient human TPO-transgenic mice.

33 elanoma growth in immunocompetent but not in immunodeficient (IFNgamma(-/-), nude, or CD8(-/-)) mice.

34 tes to these disappointing outcomes using an immunodeficient IL2 receptor gamma (IL2rgamma)-null mous

35 /-)) Ag-specific Tfh cells were used to help immunodeficient Il21r(-/-) B cells following T-dependent

36 ontrast to nonobese diabetic severe combined immunodeficient Il2rg(-/-) (NSG) mice, human NK cells in

37 Immunodeficient individuals who excrete vaccine-derived

38 a (KS), a vascular tumor frequently found in immunodeficient individuals.

39 ypes, including nonhematopoietic cells, into immunodeficient mice (lung-only mice) resulted in the de

40 t tumors resembling early-stage SCLC grew in immunodeficient mice after subcutaneous injection of PNE

41 Immunodeficient mice are now readily engrafted with huma

42 s were transplanted under the KC of diabetic immunodeficient mice at a marginal dose (500 islet equiv

43 T1D, we developed a viral infection model in immunodeficient mice bearing human islet grafts.

44 Since the description of immunodeficient mice bearing mutations in the IL2 recept

45 In severe combined immunodeficient mice bearing SKOV3 tumors, 7 was efficac

46 mal imaging was performed in severe combined immunodeficient mice bearing solid and disseminated MM t

47 Severe combined immunodeficient mice bearing uveal melanoma tumors or en

48 oliferation in vitro or tumor progression in immunodeficient mice but completely impaired GBM progres

49 PV1/MusPV1) induces persistent papillomas in immunodeficient mice but not in common laboratory strain

50 eate primary gastrointestinal (GI) tumors in immunodeficient mice by tail-vein injection rather than

51 ng the (68)Ga radioisotope and injected into immunodeficient mice can be tracked in real time from th

52 Immunodeficient mice carrying a human SIRPA transgene ha

53 AIRE levels in human thymus grafted in immunodeficient mice depended upon the sex of the recipi

54 an in vivo synthetic niche in the dermis of immunodeficient mice driving the differentiation of cDCs

55 Administering REGN421 to immunodeficient mice engineered to express human Dll4 in

56 y of TCR-transduced T cells was confirmed in immunodeficient mice engrafted with a human AML cell lin

57 Immunodeficient mice engrafted with either normal or can

58 Immunodeficient mice engrafted with functional human cel

59 Immunodeficient mice engrafted with human peripheral blo

60 Patient-derived xenograft tumours growing in immunodeficient mice exhibited enhanced hypoxia compared

61 nder the renal capsule of the left kidney in immunodeficient mice followed by the implantation of a t

62 Intrabone marrow transplantation into immunodeficient mice further showed that MA4 and KRAS(G1

63 transplanted into the subcutaneous space of immunodeficient mice generated fewer functional blood ve

64 ited by 3'3'-cGAMP injection in syngeneic or immunodeficient mice grafted with multiple myeloma.

65 Xenograft cell transplantation into immunodeficient mice has become the gold standard for as

66 Cell transplantation into immunodeficient mice has revolutionized our understandin

67 Humanized immune system immunodeficient mice have been extremely useful for the

68 Immunodeficient mice have been used predominantly in bio

69 and significantly prolonged the survival of immunodeficient mice implanted with the transformed HCD-

70 T cell activation when used to reconstitute immunodeficient mice in the presence of scurfy fetal liv

71 progenitor cells and reduced their growth in immunodeficient mice in vivo, in comparison with NIL alo

72 ells infected with a LMP1-deficient EBV into immunodeficient mice induces B cell lymphomas.

73 Only sickness symptoms were evident in immunodeficient mice infected with T. gondii, as associa

74 Severely immunodeficient mice inoculated with myeloid-restricted

75 w humanized mouse model consisting of highly immunodeficient mice intrasplenically injected with peri

76 ovel preclinical in vivo model consisting of immunodeficient mice intrasplenically injected with peri

77 nsplantation into naive mice, but survive in immunodeficient mice lacking B cells.

78 from the brain when transferred to infected immunodeficient mice lacking T cells.

79 Nonobese diabetic severe combined immunodeficient mice lacking the cytokine receptor commo

80 of CD4(+)CD45RB(hi)Nlrp12(-/-) T cells into immunodeficient mice led to more severe colitis and atop

81 landular transplantation of cultured MSCs in immunodeficient mice led to their engraftment in the inj

82 eekly injections of 1 mg kg(-1) of mRNA into immunodeficient mice maintain trough VRC01 levels above

83 orted that reconstitution of CD3+ T cells in immunodeficient mice mimics ART-induced bone loss observ

84 have focused on the historic development of immunodeficient mice over the last 2 decades, as well as

85 iviral MYC vector and then transplanted into immunodeficient mice produced a hierarchically organized

86 g high throughput TCRbeta CDR3 sequencing in immunodeficient mice receiving human hematopoietic stem

87 ers as fetal human thymus (HU THY) grafts in immunodeficient mice receiving the same human CD34(+) ce

88 had approximately equal abilities to infect immunodeficient mice reconstituted with a human hematopo

89 Immunodeficient mice reconstituted with a human immune s

90 nsplantation into immunocompetent as well as immunodeficient mice resulted in a strong reduction of t

91 in human cancer cell lines xenografted into immunodeficient mice resulted in activation of canonical

92 antation of transduced FA CD34(+) cells into immunodeficient mice resulted in reproducible engraftmen

93 Transplantation of CYTH1-knockdown cells to immunodeficient mice resulted in significantly lower lon

94 NPM-ALK-transformed CD4+ T lymphocytes into immunodeficient mice resulted in the formation of tumors

95 c implant of CCA human cells in the liver of immunodeficient mice resulted in the release to serum of

96 f splenocytes and experiments in genetically-immunodeficient mice reveal the importance of both T and

97 ed with small hairpin RNA (shRNA)-STAT3 into immunodeficient mice revealed a decrease in the number o

98 e seminiferous tubules of germ cell-depleted immunodeficient mice revealed divergent fates of iPSCs p

99 Human pancreatic islets engrafted into immunodeficient mice serve as an important model for in

100 alp hair follicles onto chemotherapy-treated immunodeficient mice serves as an excellent in vivo mode

101 esis that human cells grown as xenografts in immunodeficient mice should produce equivalent immunopep

102 n of day 20 CMs into the infarcted hearts of immunodeficient mice showed good engraftment, and echoca

103 transplantation of corrected WAS HSPCs into immunodeficient mice showed persistence of edited cells

104 te tumor xenografts in ovariectomized female immunodeficient mice supplemented with 17beta-estradiol.

105 gical tolerance unfold in mutant mice and in immunodeficient mice that received p53cKO-derived thymoc

106 was induced in human arteries engrafted into immunodeficient mice that were reconstituted with T cell

107 esponse of human hair follicles grafted onto immunodeficient mice to cyclophosphamide resembles the k

108 t diseases, followed by transplantation into immunodeficient mice to generate genetic models of clona

109 eight participants were then inoculated into immunodeficient mice to test for infectivity.

110 These models generally consist of immunodeficient mice transplanted with human cells or re

111 y positron emission tomography as well as in immunodeficient mice transplanted with human islets unde

112 nt donor cells were significantly reduced in immunodeficient mice transplanted with MF CD34(+) cell g

113 Immunodeficient mice transplanted with myelofibrosis pat

114 Human lymphocytes transferred into immunodeficient mice underwent activation and redistribu

115 r radical cure of experimental babesiosis in immunodeficient mice using a combination of an endochin-

116 g effect of hypoxia on tumor initiation into immunodeficient mice using human non-small lung carcinom

117 of CCA tumors subcutaneously implanted into immunodeficient mice was inhibited by 5-fluorouracil.

118 of CCA tumors subcutaneously implanted into immunodeficient mice was inhibited by 5-FU.

119 allergen-induced gut and lung inflammation, immunodeficient mice were engrafted with PBMCs from thes

120 CD-1 nude immunodeficient mice were split into four experimental g

121 M21 (human melanoma)-bearing severe combined immunodeficient mice were used for biodistribution, PET

122 ty and efficacy in targeting brain tumors in immunodeficient mice when the MLD was expressed within t

123 monstrated in human CD46 transgenic mice and immunodeficient mice with engrafted human CD34(+) cells

124 n the spinal cord and dorsal root ganglia of immunodeficient mice with higher efficacy than AAV2, 5,

125 third model was generated by reconstituting immunodeficient mice with human CD34+ hematopoietic stem

126 n HD glial chimeras by neonatally engrafting immunodeficient mice with mutant huntingtin (mHTT)-expre

127 Severe combined immunodeficient mice xenografted with M21 human melanoma

128 metastasis, and mortality of severe combined immunodeficient mice xenografted with PC3 or DU145 cells

129 Subsequently, PET imaging was performed on immunodeficient mice xenografted with these cell lines.

130 HSCs with >6-month repopulating activity in immunodeficient mice) displayed rapid increases in activ

131 mice, immunocompetent, or in severe combined immunodeficient mice, and after treatment with an immuno

132 d human TECs, human thymic tissue grafted to immunodeficient mice, and murine fetal thymus organ cult

133 ient-derived RCC samples into the kidneys of immunodeficient mice, as well as the s.c. implantation f

134 antitumor activity in immunocompetent versus immunodeficient mice, demonstrating a contribution of th

135 When transplanted into immunodeficient mice, FOXP3-expressing HSC showed signif

136 myeloid cells in vitro and can also engraft immunodeficient mice, generating myeloerythoid and B-lym

137 Upon transplantation in immunodeficient mice, grafted cells form vascularized is

138 Skin models, in culture and xenografts in immunodeficient mice, have potential for research on vir

139 t ZIKV infection in both immunocompetent and immunodeficient mice, highlighting the value of NS1 as a

140 studying human malignant and normal HSCs in immunodeficient mice, including newly developed mice for

141 ative capacity in either immune-competent or immunodeficient mice, indicating a critical need for imp

142 euroblastoma tumor engraftment and growth in immunodeficient mice, indicating an effect independent o

143 es decreased and was comparable to uptake in immunodeficient mice, indicating saturation of CD3 bindi

144 effect of DS-5272 is markedly attenuated in immunodeficient mice, indicating the critical impact of

145 in vivo human GBM xenograft experiments with immunodeficient mice, mAb treatment inhibited growth of

146 When xenografted into the cerebellum of immunodeficient mice, medulloblastoma cells with stable

147 In immunodeficient mice, NKG2Anull NK cells were significan

148 tive transfer experiments into tumor-bearing immunodeficient mice, NKG2Anull NK cells were significan

149 ng PARN mutations were xenotransplanted into immunodeficient mice, oral treatment with a repurposed P

150 When transplanted into immunodeficient mice, P2RY1(+)/ALK3(bright+) populations

151 In immunodeficient mice, physiologic levels of murine Epo w

152 tation of miR-377 silenced hCD34(+) cells in immunodeficient mice, promoting neovascularization (at 2

153 erved in wild-type mice and was abrogated in immunodeficient mice, suggesting that the antitumor acti

154 When transplanted into diabetic, immunodeficient mice, the epigenetically edited islets s

155 When transplanted to immunodeficient mice, these variant clones induced patho

156 generate leukemia upon transplantation into immunodeficient mice, thus providing formal evidence tha

157 Following engraftment into immunodeficient mice, transduced HSPCs give rise to huma

158 ong-term reconstitution when transplanted in immunodeficient mice, were present in the chorion from 1

159 andates awareness of replicating MuLV in NOD immunodeficient mice, which can significantly influence

160 erformed in tumour xenografts in 15 NCr nude immunodeficient mice, which were treated with either the

161 y, we unintentionally generated RV-resistant immunodeficient mice, which, we hypothesized, reflected

162 firmed by enhanced tumor-forming capacity in immunodeficient mice.

163 P) effectively suppresses PEL progression in immunodeficient mice.

164 th rates of BCSC-derived tumor xenografts in immunodeficient mice.

165 autologous transplantation or infusion into immunodeficient mice.

166 induced by the transfer of human T cells in immunodeficient mice.

167 in vivo after transplantation into humanised immunodeficient mice.

168 cells and failure to establish leukaemia in immunodeficient mice.

169 ike particles in vitro and when infused into immunodeficient mice.

170 ng and developing proliferation advantage in immunodeficient mice.

171 ring glioma growth in immunocompetent versus immunodeficient mice.

172 m the corrected cell clone were grafted onto immunodeficient mice.

173 rowth in human lung carcinoma xenografted in immunodeficient mice.

174 in soft agar and rapidly produced tumors in immunodeficient mice.

175 of samples that would not engraft the BM of immunodeficient mice.

176 and attenuated xenograft tumor formation in immunodeficient mice.

177 sfully passaged for at least three rounds in immunodeficient mice.

178 angiogenesis and peritoneal tumor growth in immunodeficient mice.

179 ntial of BCP-ALL cells xenotransplanted into immunodeficient mice.

180 term engraftment of human CML CD34+ cells in immunodeficient mice.

181 anoid culture before being transplanted into immunodeficient mice.

182 ard H460 tumor xenografts in severe-combined immunodeficient mice.

183 to high titers in cultured cell lines and in immunodeficient mice.

184 as potentiates their tumorigenic activity in immunodeficient mice.

185 ity and promoted malignant transformation in immunodeficient mice.

186 ect and grow in the tissues of wild-type and immunodeficient mice.

187 outgrowth of human multiple myeloma cells in immunodeficient mice.

188 d lineages and engraft primary and secondary immunodeficient mice.

189 nced EMT and CSC markers and tumor growth in immunodeficient mice.

190 diac repair and function after I-R injury in immunodeficient mice.

191 Kidneys were orthotopically allografted to immunodeficient mice.

192 d state in stroma coculture and engrafted in immunodeficient mice.

193 imary and metastatic human breast cancers in immunodeficient mice.

194 of genetically corrected patient cells into immunodeficient mice.

195 l of glycerol-induced AKI in severe combined immunodeficient mice.

196 t are defined by their ability to engraft in immunodeficient mice.

197 dependent gut inflammation in PBMC-engrafted immunodeficient mice.

198 rofiles and generate intracranial tumours in immunodeficient mice.

199 effector clones capable of engraftment into immunodeficient mice.

200 ion and in vivo tumors after xenografting in immunodeficient mice.

201 somes and CLL cells promoted tumor growth in immunodeficient mice.

202 cell growth in vitro and in severe combined immunodeficient mice.

203 mor-initiating capacity of ALDH(hi) cells in immunodeficient mice.

204 elanoma cells injected intracutaneously into immunodeficient mice.

205 CIK cells delayed autologous tumor growth in immunodeficient mice.

206 y, and tumorigenicity following injection in immunodeficient mice.

207 e treated with AZD1480 and transplanted into immunodeficient mice.

208 learance while sparing uninjected tumours in immunodeficient mice.

209 mental genesis of a human AML in xenografted immunodeficient mice.

210 xcess viable tumor was implanted into highly immunodeficient mice.

211 or clearance in syngeneic mice compared with immunodeficient mice.

212 mal cells enabling growth in soft agar or in immunodeficient mice.

213 lineages derived from HSCs transplanted into immunodeficient mice.

214 ced T cells eliminated Pik3ca-null tumors in immunodeficient mice.

215 d/or injected into flanks of severe combined immunodeficient mice; xenograft tumor growth and metasta

216 such cells through immunocompetent (but not immunodeficient) mice.

217 nsfer to Prkdc(scid)-mutant (severe combined immunodeficient) mice.

218 otransplantation model in cytokine-humanized immunodeficient "MISTRG" mice that provides efficient an

219 n ECs lining human coronary artery grafts in immunodeficient mouse hosts by alloantibody and compleme

220 east 4 to 6 weeks after transplantation into immunodeficient mouse hosts.

221 ng was evaluated both in vitro and within an immunodeficient mouse model of autologous sarcoma.

222 cells and promotes osteolysis in vivo in an immunodeficient mouse model of bone metastasis through u

223 of a DMD patient (mdcs) transplanted into an immunodeficient mouse model of DMD, we report that two n

224 In an immunodeficient mouse model of dormant breast cancer, th

225 Following inoculation of a highly sensitive immunodeficient mouse model, crucial immune parameters,

226 duce functional improvement in an all-female immunodeficient mouse model.

227 We describe two novel immunodeficient mouse models of hyperlipidemia (Rag1(-/)

228 pe (89)Zr and studied in immunocompetent and immunodeficient mouse models.

229 the number of TUNEL+ cells in non-dystrophic immunodeficient mouse muscles and it only slightly enhan

230 The development of highly immunodeficient mouse strains into which human immune sy

231 The development of immunodeficient mouse strains with high-level engraftmen

232 islets by [(11)C]AZ12204657 was shown in the immunodeficient mouse transplantation model.

233 rial transfer was observed in vivo in an NSG immunodeficient mouse xenograft model and also occurred

234 ve activities in TSC2-deficient cells and an immunodeficient mouse xenograft model of lymphangioleiom

235 t also inhibited tumor growth in vivo in two immunodeficient mouse xenograft models.

236 Immunodeficient mouse-human chimeras provide a powerful

237 ability of MDS stem cells to engraft current immunodeficient murine hosts.

238 Immunodeficient MyD88-knockout mice infected with S. aur

239 nes, and human B cell activation factor into immunodeficient NOD scid gamma (NSG) mice by the use of

240 Here we utilized immunodeficient NOD-scid IL2rgamma(null) (NSG) mice that

241 ns of mice (C57BL/6, BALB/c, or the severely immunodeficient NOD-scid,gammac(null) [NSG]).

242 or spots, and tumor burden in BLCL-engrafted immunodeficient NOD-SCID/Il2rg(-/-) mice.

243 D19(+) B cell population after transfer into immunodeficient NOD.Cg-Prkdc(scid) Il2rg(tm1wjl)/SxJ neo

244 Immunodeficient NOD.Cg-Prkdc(scid)IL2rg(tm1Wjl)(NSG) mic

245 abeled cell sorting and transplantation into immunodeficient NOD/SCID/interleukin 2 receptor gamma ch

246 ne on male nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice bearing human PSMA(+) PC

247 Human but not mouse islets transplanted into immunodeficient NSG mice effectively accumulate lipid dr

248 ells from giant cell arteritis patients into immunodeficient NSG mice engrafted with human arteries.

249 one marrow (BM) cells were transplanted into immunodeficient NSG mice to generate an immunocompetent

250 r (control) and subcutaneously injected into immunodeficient NSG mice.

251 166(-) cells to the bone marrow of engrafted immunodeficient NSG mice.

252 S/G2-phase human HSCs after engraftment into immunodeficient (NSG) mice, a phenotype that is associat

253 s (HSPCs) expressing MLL-AF9 or MLL-Af4 into immunodeficient NSGS mice, which strongly promote myeloi

254 In immunodeficient or chemotherapy-treated mice, the intest

255 None of these children were considered immunodeficient or had an increased frequency of infecti

256 from a patient's tumor are implanted into an immunodeficient or humanized mouse.

257 g systemic injection of ICL-labeled cells in immunodeficient or immunocompetent mice, few cells arriv

258 is usually safe but cannot be given to many immunodeficient patients and retains the capacity to est

259 Immunodeficient patients are particularly vulnerable to

260 rvations support the concept that some DOCK8-immunodeficient patients have mutable mosaic genomes tha

261 Immunodeficient patients who have received therapeutic h

262 nalizes more than 60 mutations identified in immunodeficient patients, as well as a large body of gen

263 ines are essential for disease prevention in immunodeficient patients, just as they are for healthy s

264 methicillin-resistant S. aureus infection in immunodeficient patients.

265 e etiology of chronic meningoencephalitis in immunodeficient patients.

266 unity is important for clinical decisions in immunodeficient patients.

267 1-/- mice survived significantly longer than immunodeficient Pfp-/- Rag2-/- mice.

268 iated NOD2 mutations could cause a primarily immunodeficient phenotype by selectively impairing TLR4-

269 ous or compound heterozygous state cause the immunodeficient phenotype.

270 tcome relative to mice, we worked to develop immunodeficient rabbits by CRISPR/Cas9.

271 icient rabbits, as well as multigenic mutant immunodeficient rabbits have been produced.

272 of SGM (e.g. FOXN1, RAG2, IL2RG, and PRKDC) immunodeficient rabbits, as well as multigenic mutant im

273 ng antibodies or anti-IFNAR1 antibody and in immunodeficient Rag1 KO mice.

274 By serially transplanting hyperplasias into immunodeficient rag1 mutant zebrafish, we succeeded in l

275 Immunodeficient RAG2 knock-out mice were unable to contr

276 We focused on developing immunodeficient rag2(-)/(-) model of ALS with lower numb

277 Immunodeficient Rag2(-/-)gamma(c)(-/-)CD47(-/-) C57BL/6

278 vertheless, when adoptively transferred into immunodeficient Rai(+/+) mice, these cells promoted a mo

279 A novel immunodeficient rat model supports human lung cancer xen

280 We generated immunodeficient Rat Rag-/- Gamma chain-/- human signal r

281 nto neural stem cells and grafted into adult immunodeficient rats after spinal cord injury.

282 Immunodeficient rats have been generated but human immun

283 SCs that were implanted into sites of SCI in immunodeficient rats over a period of 1.5 years.

284 nctive B cell progeny when transplanted into immunodeficient recipients, supporting a two-pathway mod

285 ma cells were implanted into the striatum of immunodeficient RNU rats.

286 Using immunodeficient SCID mice, we focused on targeting human

287 which is nearly completely abolished in the immunodeficient SCID/beige (bg) variant.

288 racteristics were studied in severe combined immunodeficient (SCID) mice inoculated with activated hP

289 Severe combined immunodeficient (SCID) mice were infected and treated wi

290 Inoculation of severe combined immunodeficient (SCID) mice yielded isolates from 5 of 5

291 RAG1-mutants from severe combined immunodeficient (SCID) patient cells showed a failure to

292 In liver-humanized uPA/severe combined immunodeficient (SCID)/beige mice challenged with HBV in

293 In conclusion, the severely immunodeficient SD-RG rats support fast growth of PDX co

294 ll studied of these hosts, with a variety of immunodeficient strains available for various specific u

295 nd cellular vaccine responses in healthy and immunodeficient subjects and how that knowledge can then

296 -DFO-N-suc-muS110 spleen uptake was lower in immunodeficient than in immunocompetent mice.

297 elicited opposite effects on tumor growth in immunodeficient tumor-bearing mice.

298 Consequently, SD-RG rats are severely immunodeficient with an absence of mature T, B, and NK c

299 dren (median age, 7.3 years), 59.2% severely immunodeficient, with suspected tuberculosis in Southeas

300 Studies in immunodeficient xenograft models have identified local i